POPULATION PHARMACOKINETICS OF A NOVEL TGF-BETA RECEPTOR I KINASE INHIBITOR VACTOSERTIB IN PATIENTS WITH ADVANCED-STAGE SOLID TUMORS.

被引：0

作者：

Lee, J. I. ^{[1
]}

Jung, S. Y. ^{[1
]}

Yug, J. S. ^{[2
]}

Chung, E. K. ^{[2
]}

Keedy, V. L. ^{[3
]}

Bauer, T. M. ^{[4
,5
]}

Clarke, J. M. ^{[6
]}

Hurwitz, H. ^{[6
]}

Lee, H. ^{[7
]}

Park, N. ^{[7
]}

Lee, S. ^{[7
]}

Kim, H. -K. ^{[7
]}

Baek, I. ^{[8
]}

Hwang, S. ^{[8
]}

Nam, S. Y. ^{[8
]}

Ha, I. ^{[8
]}

Kim, S. -J. ^{[8
]}

机构：

[1] Seoul Natl Univ, Seoul, South Korea

[2] Kyung Hee Univ, Seoul, South Korea

[3] Vanderbilt Univ, Med Ctr, Nashville, TN USA

[4] Sarah Cannon Res Inst, Nashville, TN USA

[5] Tennessee Oncol, Nashville, TN USA

[6] Duke Univ, Med Ctr, Durham, NC USA

[7] Natl Canc Ctr, Natl OncoVenture, Goyang, South Korea

[8] MedPacto Inc, Suwon, South Korea

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2019年 / 105卷

关键词：

D O I：

暂无

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

PIII-074

引用

页码：S103 / S103

页数：1

共 50 条

[1] Population pharmacokinetics of vactosertib, a new TGF-β receptor type Ι inhibitor, in patients with advanced solid tumors
Su Young Jung
Ji Seob Yug
Jeffery M. Clarke
Todd M. Bauer
Vicki L. Keedy
Sunjin Hwang
Seong-Jin Kim
Eun Kyoung Chung
Jangik I. Lee
Cancer Chemotherapy and Pharmacology, 2020, 85 : 173 - 183
[2] Population pharmacokinetics of vactosertib, a new TGF-β receptor type Ι inhibitor, in patients with advanced solid tumors
Jung, Su Young
Yug, Ji Seob
Clarke, Jeffery M.
Bauer, Todd M.
Keedy, Vicki L.
Hwang, Sunjin
Kim, Seong-Jin
Chung, Eun Kyoung
Lee, Jangik I.
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2020, 85 (01) : 173 - 183
[3] Phase 1 study of galunisertib, a TGF-beta receptor I kinase inhibitor, in Japanese patients with advanced solid tumors
Fujiwara, Yutaka
Nokihara, Hiroshi
Yamada, Yasuhide
Yamamoto, Noboru
Sunami, Kuniko
Utsumi, Hirofumi
Asou, Hiroya
Takahash, Osamu, I
Ogasawara, Ken
Gueorguieva, Ivelina
Tamura, Tomohide
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 76 (06) : 1143 - 1152
[4] Phase 1 study of galunisertib, a TGF-beta receptor I kinase inhibitor, in Japanese patients with advanced solid tumors
Yutaka Fujiwara
Hiroshi Nokihara
Yasuhide Yamada
Noboru Yamamoto
Kuniko Sunami
Hirofumi Utsumi
Hiroya Asou
Osamu TakahashI
Ken Ogasawara
Ivelina Gueorguieva
Tomohide Tamura
Cancer Chemotherapy and Pharmacology, 2015, 76 : 1143 - 1152
[5] A phase I study of a TGF-β receptor I kinase inhibitor YL-13027 in patients with advanced solid tumors.
Li, Jin
Liu, Tianshu
Bao, Hanying
Xu, Zusheng
Shu, Yang
Zheng, Binghua
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[6] Association of TGF-β responsive signature with anti-tumor effect of vactosertib, a potent, oral TGF-β receptor type I (TGFBRI) inhibitor in patients with advanced solid tumors.
Keedy, Vicki Leigh
Bauer, Todd Michael
Clarke, Jeffrey Melson
Hurwitz, Herbert
Baek, Insun
Ha, Ilho
Ock, Chan-Young
Nam, Su Youn
Kim, Mina
Park, Neunggyu
Kim, Jung Yong
Kim, Seong-Jin
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[7] POPULATION PHARMACOKINETICS OF GLASDEGIB IN PATIENTS WITH ADVANCED HEMATOLOGIC AND SOLID TUMORS.
Lin, S.
Shaik, M.
Ruiz, A.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 103 : S78 - S78
[8] Population pharmacokinetics of NKTR-102, a topoisomerase I inhibitor-polymer conjugate, in patients with advanced solid tumors.
Eldon, M. A.
Hoch, U.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[9] Preclinical Efficacy of TGF-Beta Receptor I Kinase Inhibitor, Galunisertib, in Myelofibrosis
Yue, Lanzhu
Bartenstein, Matthias
Zhao, Wanke
Ho, Wan-Ting
Zhang, Ling
Rapaport, Franck
Levine, Ross L.
Shao, Zonghong
Zhao, Zhizhuang Joe
Verma, Amit
Epling-Burnette, Pearlie K
BLOOD, 2015, 126 (23)
[10] A novel TGF-beta receptor I kinase inhibitor demonstrated to be an effective immuno-therapy for cancer
Xu, Zusheng
Lou, Yangtong
Chen, Li
Zeng, Kun
Sun, Qingrui
Qu, Yingying
Wang, Wei
Wu, Xiaodong
Ge, Xiaomei
Gu, Ying
Zhang, Yingjia
Zhou, He
CANCER RESEARCH, 2017, 77

← 1 2 3 4 5 →